US Stock Market Move | Alopexx (ALPX.US) debuts on the US stock market, with its stock price soaring over 96% after opening.

On Tuesday, Alopexx (ALPX.US) made its debut on the US stock market, with the opening stock price skyrocketing. As of the time of writing, the stock has surged over 96%, reaching $9.84. The IPO price was $5. The company focuses on developing immune therapies for bacterial, fungal, and parasitic infections. Alopexx's core investigational drug, F598, has completed Phase I clinical trials and Phase II preliminary trials, showing good tolerance with no serious adverse reactions. The drug can provide immediate protection for two to three months with a single infusion. The company plans to conduct clinical trials of F598 for ICU patients with high incidence of infections in hospitals, aiming to establish it as a standard treatment for preventing and improving gram-negative, gram-positive, and fungal infections.